ViewPoint develops a nonsurgical route to cataract treatment.
Cypre and Molecular Devices sign co-marketing agreement to collaborate on delivering solutions for screening biologically relevant assays
Kolin Hribar, PhD, CEO and Founder of Cypre Inc. with their Symphony®/VersaGel® Cypre and Molecular Devices signed a co-marketing agreement to jointly market Cypre’s Symphony®/VersaGel® 3D cel [...]
After completing their graduate work at Stanford, Trevor Martin and Ashley Tehranchi took 2 benches at MBC BioLabs to launch Mammoth Biosciences. Now, only seven months later, they and their colleagu [...]
Expanding the capabilities of our FastTrack Core, LI-COR has placed their Odyssey CLx infrared imaging system at both MBC BioLabs Bay Area locations. The instrument’s broad, linear dynamic range accur [...]
Proceeds will advance lead product candidate through clinical proof-of-concept studies in cataracts and presbyopia Series B led by The Rise Fund, a global impact fund SAN FRANCISCO, Calif., March 5, [...]
to Develop Improved Screening and Early Diagnosis Tests for Type 1 Diabetes Enable Biosciences, a UC Berkeley and Stanford-StartX diagnostics company at MBC BioLabs, and Stanford’s Division of Pediat [...]
to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment Pionyr Immunotherapeutics, a company at QB3@953, is developing antibody therapeutics that increase the body's antitumor imm [...]